Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial

SC Bain, O Mosenzon, R Arechavaleta… - Diabetes, Obesity …, 2019 - Wiley Online Library
Aims To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation
of a glucagon‐like peptide‐1 receptor agonist. Materials and methods PIONEER 6 is a …
被引用次数：108 相关文章
[PDF] ru.nl

[PDF][PDF] Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

SC Bain, O Mosenzon, R Arechavaleta, P Bogdanski… - 2019 - repository.ubn.ru.nl
Aims: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet
formulation of a glucagon-like peptide-1 receptor agonist. Materials and methods: PIONEER …

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

S Bain, O Mosenzon, R Arechavaleta… - DIABETES OBESITY …, 2019 - avesis.deu.edu.tr
Aims To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation
of a glucagon-like peptide-1 receptor agonist. Materials and methods PIONEER 6 is a …
[HTML] nih.gov

[HTML][HTML] Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

SC Bain, O Mosenzon, R Arechavaleta… - Diabetes, Obesity & …, 2019 - ncbi.nlm.nih.gov
Aims To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation
of a glucagon‐like peptide‐1 receptor agonist. Materials and methods PIONEER 6 is a …

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

SC Bain, O Mosenzon… - Diabetes, Obesity …, 2019 - portal.findresearcher.sdu.dk
Aims: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet
formulation of a glucagon-like peptide-1 receptor agonist. Materials and methods: PIONEER …

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

SC Bain, O Mosenzon… - Diabetes, Obesity …, 2019 - ohiostate.elsevierpure.com
Aims: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet
formulation of a glucagon-like peptide-1 receptor agonist. Materials and methods: PIONEER …

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.

SC Bain, O Mosenzon, R Arechavaleta… - Diabetes, Obesity & …, 2018 - europepmc.org
Aims To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation
of a glucagon-like peptide-1 receptor agonist. Materials and methods PIONEER 6 is a …

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

SC Bain, O Mosenzon, R Arechavaleta… - DIABETES, OBESITY …, 2019 - ricerca.unich.it
AIMS: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet
formulation of a glucagon-like peptide-1 receptor agonist. MATERIALS AND METHODS …

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.

SC Bain, O Mosenzon, R Arechavaleta… - Diabetes, Obesity & …, 2019 - search.ebscohost.com
Aims: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet
formulation of a glucagon‐like peptide‐1 receptor agonist. Materials and methods …

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

SC Bain, O Mosenzon, R Arechavaleta, P Bogdański… - 2019 - pubmed.ncbi.nlm.nih.gov
Aims To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation
of a glucagon-like peptide-1 receptor agonist. Materials and methods PIONEER 6 is a …